Merck’s KEYNOTE-756 Hits One Primary Endpoint, But Don’t Pop The Champagne Yet
Executive Summary
The study, in ER+/HER2- breast cancer, met the pCR co-primary endpoint. Merck previously tried without success to win accelerated approval for Keytruda in TNBC using pCR as a surrogate for EFS.